$995 | Single User
$1990 | Site License
$2495 | Global License

Non-Small Cell Lung Cancer: Update Bulletin
[Jan 2016]
[Lowest Price Guaranteed: $995]

Published by FirstWord Pharma: 01 Jan 2016 | 295 | In Stock
Related Topics: AstraZeneca , Cancer , Lilly , Lung Cancer , Pfizer , Roche



Gain new KOL insights on the latest events that have the potential to shape the targeted treatment of Non-Small Cell Lung Cancer (NSCLC). Topics covered include opinions about Tagrisso (osimertinib; AstraZeneca) as a newly approved second-line treatment for EGFR T790M mutation-positive NSCLC, the approval of Portrazza (necitumumab; Eli Lilly) for first-line squamous NSCLC therapy, and the expansion of the label for Xalkori (crizotinib; Pfizer) to include the first-line treatment of patients in the EU with ALK-positive NSCLC and patients in the US with ROS1-positive advanced NSCLC. KOLs also discuss Alecensa (alectinib; Roche) following its approval as a second-line treatment for ALK-positive metastatic NSCLC, and assess topline KEYNOTE-010 trial data for Keytruda (pembrolizumab; Merck & Co.) in the second-line treatment of PD-L1 positive advanced NSCLC.

Puchase Reasons

Key Questions Answered in this Update Bulletin:

  • Will the safety and efficacy of AstraZeneca’s Tagrisso prove sufficient to position it as the second-line treatment of choice for EGFR T790M mutation-positive NSCLC?

  • Is the overall survival (OS) advantage shown by Eli Lilly’s Portrazza over chemotherapy likely to justify its cost as a first-line therapy for squamous NSCLC?

  • If approved, how widespread is the use of Pfizer’s Xalkori as a first-line treatment for ALK-positive advanced NSCLC, in the EU, likely to be?

  • As Xalkori awaits approval for the treatment of ROS1-positive metastatic NSCLC in the US, how successful do KOLs think the agent will be in this setting?

  • Can the favourable toxicity profile and significant CNS activity of Roche’s Alecensa help it to secure a role as standard treatment for second-line ALK-positive metastatic NSCLC?

  • To what extent will the OS advantage shown by topline KEYNOTE-010 data impact the use of Merck’s Keytruda as a second-line treatment for PD-L1 positive advanced NSCLC?

  • Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.

    Table of Contents
    for Non-Small Cell Lung Cancer: Update Bulletin [Jan 2016]

    Additional Details


    FirstWord Pharma

    Publisher Information


    295 |

    Report Format


    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    Physician Views: Is the HER2-positive breast cancer extended adjuvant opportunity big enough to support neratinib's blockbuster forecasts?
    Scope Top-line data from the ExteNET study – which were released earlier this week – appear to estab...
    28 Jul 2014 by FirstWord Pharma USD $695 More Info
    Physician Views: Avastin to lose share as front-line therapy for first-line metastatic colorectal cancer?
    Scope Two recent developments appear poised to shift the typical US-based treatment regimen for firs...
    13 Jul 2014 by FirstWord Pharma USD $695 More Info
    The Future of Cancer Immunotherapy: KOL Views Bring Opportunities into Sharp Focus
    IntroductionThere has been considerable media hype and clinical interest in cancer immunotherapy in ...
    01 Jul 2014 by FirstWord Pharma USD $4,995 More Info
    Physician Views: Expanded access in cancer – how are oncologists utilising this opportunity?
    Scope According to analysts at Barclays, oncology continues to attract around one-third of pharma's ...
    28 Apr 2014 by FirstWord Pharma USD $695 More Info
    Breast Cancer: New targeted therapies transform treatment - KOL Insight
    IntroductionThe introduction of targeted therapies revolutionised the breast cancer market, widening...
    10 Feb 2014 by FirstWord Pharma USD $7,900 More Info
    Physician Views: Bayer's M&A catalyst – is Xofigo a paradigm shifter for the prostate cancer market?
    Scope Already positioned as one of the most commercially promising new drug approvals of 2013, Alget...
    01 Dec 2013 by FirstWord Pharma USD $695 More Info
    KOL Insight: Prostate Cancer: Competition intensifies in race to the top
    IntroductionThe Prostate Cancer market has seen a number of progressive changes in recent years. The...
    01 Nov 2013 by FirstWord Pharma USD $7,900 More Info
    Consensus Outlook: Prostate Cancer- Competition intensifies in race to the top
    IntroductionCharting the Future Prostate Cancer Market LandscapeThe prostate cancer market has exper...
    01 Nov 2013 by FirstWord Pharma USD $4,995 More Info
    Colorectal Cancer -- KOL Insight Module
    IntroductionThe global market for colorectal cancer (CRC) drugs is undergoing a fundamental shift du...
    01 Oct 2013 by FirstWord Pharma USD $7,900 More Info
    Physician Views: What is reaction among urologists, oncologists to the Xtandi PREVAIL data – can it displace Zytiga in the pre-chemotherapy prostate cancer setting?
    ScopeThe prostate cancer market looks poised to enter its next stage of evolution in 2014, with Medi...
    01 Oct 2013 by FirstWord Pharma USD $695 More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Non-Small Cell Lung Cancer: Update Bulletin [Jan 2016] | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types


    Buy now using our secure payment system.

    We Stock...